Antigen News and Research

RSS

Navigating the dual role of B cells in tumor immunity

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

3 Jun 2025

Study: New mRNA vaccine is more scalable and adaptable to continuously evolving viruses

A new type of mRNA vaccine is more scalable and adaptable to continuously evolving viruses such as SARS-CoV-2 and H5N1, according to a study by researchers at University of Pittsburgh School of Public Health and the Pennsylvania State University.

3 Jun 2025

Engineered viruses and gene therapy halt tumor growth and extend survival in mice

This study reveals the potential of engineered phage-IL-12 therapy in melanoma, enhancing immune response and tumor destruction in aggressive cancer models.

2 Jun 2025

Universal CAR T cell therapy shows promise for aggressive T cell cancers

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results of an international phase 1/2 clinical trial led by researchers at Washington University School of Medicine in St. Louis.

31 May 2025

New trial offers hope for men with aggressive prostate cancer

Many men with aggressive prostate cancer can experience a high rate of recurrence despite treatment.

30 May 2025

Mass General Brigham researchers share cancer research discoveries at ASCO 2025

Researchers from Mass General Brigham will present research discoveries and outcomes from clinical trials in cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30-June 3, in Chicago.

30 May 2025

Pitt professor wins NSF CAREER Award for AI-driven immunotherapy research

The University of Pittsburgh's Natasa Miskov-Zivanov, assistant professor of electrical and computer engineering, has received a prestigious Faculty Early Career Development (CAREER) Award of $581,503 from the National Science Foundation (NSF) for her project titled "Artificial Intelligence-Driven Framework for Efficient and Explainable Immunotherapy Design."

30 May 2025

LUCAS technology revolutionizes rapid viral diagnostics

Mass General Brigham researchers are shining a powerful new light into the viral darkness with the development of Luminescence CAscade-based Sensor (LUCAS), a rapid, portable, highly-sensitive diagnostic tool for processing complex biological samples.

30 May 2025

Innovative technology simplifies T cell harvesting for cancer immunotherapy

CAR T cell immunotherapy, which uses a patient's own modified immune cells to find and destroy cancer cells, can produce dramatic results when treating blood cancers like lymphoma and leukemia and shows promise against solid tumors.

29 May 2025

New material could improve delivery and effectiveness of mRNA vaccines

A new material developed at Cornell University could significantly improve the delivery and effectiveness of mRNA vaccines by replacing a commonly used ingredient that may trigger unwanted immune responses in some people.

29 May 2025

Immune microRNAs drive new frontiers in cardiovascular disease research

Cardiovascular diseases (CVDs) continue to dominate global mortality statistics, with immune dysregulation emerging as a central feature in their pathogenesis.

28 May 2025

Building Bridges to Scalable Allogeneic Cell Therapy

Rui Tostoes, Chief Technology Officer at ImmuneBridge, shares how his team is redefining preclinical development and large-scale manufacturing for allogeneic cell therapies.

From Hanson Wade Group - 7th Allogeneic Cell Therapies Summit 27 May 2025

Novel immune cells identified as potential target for tuberculosis vaccines

There is no highly effective vaccine against tuberculosis (TB), which remains an infection of global concern.

26 May 2025

NUS researchers develop breakthrough gene delivery technology for immune cells

Researchers at the National University of Singapore (NUS) have developed a scalable, non-viral technology that efficiently delivers genetic material into human immune cells.

26 May 2025

Maternal RSV vaccine and nirsevimab sharply cut infant hospitalizations, new data show

Widespread use of maternal RSV vaccination and nirsevimab during the 2024–2025 U.S. RSV season led to a significant reduction in RSV-associated hospitalizations among infants aged 0–7 months. The largest benefits were seen in the youngest and most vulnerable infants, particularly during peak winter months.

20 May 2025